Skip to main content
. 2012 Aug 16;13:73. doi: 10.1186/1471-2350-13-73

Table 2.

Molecular characterization, X-inactivation pattern and transcriptional analysis results in symptomatic and asymptomatic carriers

Carrier ID Classification DMD mutation(a) X-inactivation pattern RNA profiling Transcripts representation (wt:mutated) Total transcript level WT transcript level
C1
Symptomatic
t(X;9)(p21.1;p22.1)
100:0 (blood) 100:0 (sk.m.)
Biallelic transcript (biallelic pol. 3’-UTR)
nd
nd
nd
C2
Symptomatic
Dup exons 3–7 c.94-?_649 + ?dup (out of frame)
60:40
WT + DUP 3–7 transcripts
nd
nd
nd
C3
Symptomatic
Dup exons 5–7 c.265-?_649 + ?dup (out of frame)
75:25
WT + DUP 5–7 transcripts
70:30
nd
nd
C4
Symptomatic
Del exons 8–9 c.650-?_960 + ?del (out of frame)
86:14
WT + DEL 8–9 transcripts
50:50
17% (ex 12) 12% (ex 55)
9% (ex 12) 6% (ex 55)
C5
Symptomatic
Del exon 44 c.6291-?_6438 + ?del (out of frame)
Non Informative
WT + DEL 44 transcripts
88:12
109% (ex 12) 31% (ex 55)
96% (ex 12) 27% (ex 55)
C6
Symptomatic
Del exon 54 c.7873-?_8027 + ?del (out of frame)
54:46
WT + DEL 54 transcripts
89:11
46% (ex 12) 78% (ex 55)
41% (ex 12) 69% (ex 55)
C7
Symptomatic
Del exons 8–48 c.650-?_7098 + ?del (out of frame)
34:66
WT + DEL 8–48 transcripts
nd
nd
nd
C8
Asymptomatic
Dup 1P-7 and dup 13–42 chrX:g. (33.068.711_33.068.771) _(32.684.693_32.684.750)dup; g.(32.523.766_32.523.826)_(32.228.415_32.228.475)dup
73:27 (blood) 97:3 (sk.m.)
Biallelic transcript (biallelic ex 21 SNP)
nd
nd
nd
C9
Asymptomatic
Dup exon 2 c.32-?_93 + ?dup (out of frame)
86:14
WT + DUP 2 transcripts
74:26
36% (ex 12) 36% (ex 55)
27% (ex 12) 27% (ex 55)
C10
Asymptomatic
Dup exons 3–44 c.94-?_6438 + ?dup (in frame)
85:15
DUP 3–44 transcript (junction PCR)
nd
nd
nd
C11
Asymptomatic
Del exons 48–52 c.6913-?_7660 + ?del (out of frame)
23:77
WT + DEL 48–52 transcripts
52:48
33% (ex 12) 48% (ex 55)
17% (ex 12) 25% (ex 55)
C12
Asymptomatic
Del exons 46–51 c.6615-?_7542 + ?del (out of frame)
65:35
WT + DEL 46–51 transcripts
49:51
118% (ex 12) 128% (ex 55)
58% (ex 12) 63% (ex 55)
C13
Asymptomatic
Del exons 49–50 c.7099-?_7309 + ?del (out of frame)
44:56
WT + DEL 49–50 transcripts
87:13
43% (ex 12) 34% (ex 55)
38% (ex 12) 29% (ex 55)
C14
Asymptomatic
Del exon 52 c.7543-?_7660 + ?del (out of frame)
87:13
WT + DEL 52 transcripts
65:35
48% (ex 12) 92% (ex 55)
31% (ex 12) 60% (ex 55)
C15
Asymptomatic
Del exons 50–79 c.7201-?_(*2691_?)del
81:19
Biallelic transcript (biallelic ex 37 SNP)
nd
nd
nd
C16
Asymptomatic
Del exons 44–79 chrX:g.(28.671.682_28.671.742)_(32.170.481_32.170.541)del
53:47
Biallelic transcript (biallelic ex 21 SNP; monoallelic ex 37 SNP)
nd
nd
nd
C17
Asymptomatic
c.1615C > T (ex 14) p.R539X
42:58
WT + 1615C > T transcripts
nd
nd
nd
C18 Asymptomatic c.10033C > T (ex 69) p.R3345X 70:30 WT + 10033C > T transcripts nd nd nd

Sk.m.: skeletal muscle; WT: wild-type; MUT: mutated; nd: not determined.

a The DNA mutation numbering is based on cDNA sequence with a “c.” symbol before the number with +1 corresponding to the A of the ATG translation initiation codon in the respective reference sequence (GenBank:M18533); in carriers C8 and C16 nucleotides are numbered according to March 2006 Human Reference Sequence, NCBI Build 36.1, hg18.